Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04254263 | Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer(ATP) | recruiting | Phase 3 | 316 | RenJi HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07008976 | Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer | recruiting | Phase 3 | 246 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 14, 2025 |
| clinicaltrials |
| NCT07066280 | Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer | recruiting | Phase 3 | 326 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07057427 | Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | recruiting | Phase 3 | 812 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06839001 | CRYoablation for Small Tumors As Local Treatment - SIX Trial(CRYSTAL - SIX) | recruiting | Phase 3 | 750 | Hospital do CoracaoOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07003074 | A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer | recruiting | Phase 3 | 642 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06383767 | A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer | recruiting | Phase 3 | 378 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06915857 | Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position | recruiting | Phase 3 | 276 | Sunnybrook Health Sciences CentreOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04261244 | NeoRad Breast Cancer Study(NeoRad) | recruiting | Phase 3 | 1,826 | Bielefeld UniversityOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06958627 | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study(any) | recruiting | Phase 2 / Phase 3 | 964 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06643585 | A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse(SURVIVE HERoes) | recruiting | Phase 3 | 180 | Prof. Wolfgang JanniOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT06947330 | Comparison Between Erector Spinae Plane Block Versus Serratus Anterior Plane Block Regarding Analgesia Post Modified Radical Mastectomy(FMASUMD66/2025) | recruiting | Phase 3 | 100 | Kholoud UsamaOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06313983 | A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer | recruiting | Phase 3 | 339 | Tianjin Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05288777 | Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer(Breast53) | recruiting | Phase 2 / Phase 3 | 45 | University of VirginiaOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06926543 | Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy(CONCERT) | recruiting | Phase 3 | 858 | Dr. Tabassum WadasadawalaOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT01785420 | Pre Operative Trastuzumab in Operable Breast Cancer | recruiting | Phase 3 | 1,100 | Dr Rajendra A. BadweOTHER_GOV | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03671044 | A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients | recruiting | Phase 3 | 657 | Jina Pharmaceuticals Inc.INDUSTRY | 2 | Mar 21, 2025 | clinicaltrials |
| NCT06106529 | REDucing Hot FLASHes in Women Using Endocrine Therapy.(REDFLASH) | recruiting | Phase 3 | 260 | Reinier de Graaf GroepOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06757621 | Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer | recruiting | Phase 3 | 3,142 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06304857 | CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL(PROTECTAA) | recruiting | Phase 3 | 188 | 4th Military Clinical Hospital with Polyclinic, PolandOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06711185 | Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy(DAPA-MYOCANCER) | recruiting | Phase 3 | 80 | University of Campinas, BrazilOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05440149 | The Postoperative Radiotherapy in N1 Breast Cancer Patients(PORT-N1) | recruiting | Phase 3 | 1,106 | Seoul National University HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06044623 | Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients(IMPORTANT) | recruiting | Phase 3 | 495 | Region Örebro CountyOTHER | 6 | Nov 19, 2024 | clinicaltrials |
| NCT05063136 | Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer | recruiting | Phase 3 | 1,979 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06533384 | PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC | recruiting | Phase 3 | 310 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT04547907 | A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | recruiting | Phase 3 | 688 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06559696 | Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy | recruiting | Phase 3 | 722 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06313086 | DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer | recruiting | Phase 3 | 442 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 10, 2024 | clinicaltrials |
| NCT06341621 | Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib(Rainbow) | recruiting | Phase 3 | 1,900 | Fudan UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06268652 | Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | recruiting | Phase 3 | 302 | Sun Yat-sen UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05891093 | Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | recruiting | Phase 3 | 766 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05760378 | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | recruiting | Phase 3 | 223 | Fudan UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05159193 | Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer | recruiting | Phase 3 | 372 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04722692 | Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ(SENTINOT_2) | recruiting | Phase 3 | 500 | Uppsala UniversityOTHER | 3 | Aug 3, 2023 | clinicaltrials |
| NCT05851014 | A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | recruiting | Phase 3 | 350 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT05212454 | Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks | recruiting | Phase 3 | 400 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05804916 | Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer | recruiting | Phase 2 / Phase 3 | 556 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT04803539 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC(Artemis) | recruiting | Phase 2 / Phase 3 | 260 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03150576 | Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer(PARTNER) | recruiting | Phase 2 / Phase 3 | 780 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT04263298 | Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer | recruiting | Phase 3 | 210 | Herui YaoOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT03829553 | Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment(HARVEST) | recruiting | Phase 3 | 801 | Ruijin HospitalOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04079049 | BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases(BreCLIM-2) | recruiting | Phase 3 | 200 | Umeå UniversityOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT02535221 | Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer | recruiting | Phase 3 | 234 | Peking UniversityOTHER | 1 | Nov 29, 2021 | clinicaltrials |
| NCT05059379 | Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer(SUCLANODE) | recruiting | Phase 3 | 1,650 | Fudan UniversityOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT04137653 | Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT | recruiting | Phase 3 | 1,498 | Shengjing HospitalOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04646759 | Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer | recruiting | Phase 3 | 516 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 30, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Sep 11, 2025source: clinicaltrials